Outlook Therapeutics is a biopharmaceutical company that focuses on developing monoclonal antibodies for ophthalmic diseases. Its lead product candidate, ONS-5010, is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. The company has collaboration and license agreements with various other pharmaceutical firms.